Skip to main
CDNA
CDNA logo

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc. reported a robust revenue growth of 19% year-over-year in 2024, with expectations for an additional 17% growth in 2025, reflecting the company's strong operational momentum. The testing volume for the company reached 45,500 in 4Q24, marking a 14% increase from the previous quarter, which underlines the successful implementation of its growth strategies aimed at expanding testing services for transplant patients. Furthermore, CareDx's management has outlined strategic initiatives that target long-term revenue of $500 million and a 20% adjusted EBITDA by 2027, positioning the company favorably for sustainable future growth.

Bears say

CareDx Inc faces significant financial challenges that contribute to a negative outlook on its stock. Key risks include potential reimbursement difficulties for its testing services, which could adversely affect revenues, particularly if competitors develop superior testing alternatives. Additionally, the company’s EBITDA guidance of approximately $31 million, which fell short of market expectations, alongside risks related to regulatory changes, integration of acquisitions, and the protection of intellectual property, further heightens concerns regarding its financial stability.

CareDx (CDNA) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 11 analysts, CareDx (CDNA) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.